Clinical trials: Acute Infection Respiratory
Sepsis, Delirium
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
Ventilated ICU patients frequently have sepsis and the majority have delirium, a form of brain dysfunction that is an independent predictor of increased risk of dying, length of stay, costs, and prolonged cognitive impairment in…
- Conditions
- Sepsis, Delirium, Impaired Cognition
- Trial name
- MENDS2 (NCT01739933)
- Testing
- Dexmedetomidine, Propofol
- Where
- 11 sites in United States
- Volunteers
- 438 people
- Sponsor
- Vanderbilt University Medical Center
Respiratory Tract Infections
Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine
To describe the relief of symptoms, tolerability, and compliance of treatment with Klacid® sustained release (SR) at a dose of 1000 mg once daily in patients with acute tracheitis, acute tracheobronchitis, acute bronchitis, or in…
- Trial name
- KLARAINE (NCT01095978)
- Testing
- Clarithromycin (Klacid SR)
- Where
- 126 sites in Ukraine
- Volunteers
- 2,822 people
- Sponsor
- Abbott
Long Covid19, Long COVID
Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms
This cross-over study will assess a no added sugar diet, a restricted daily eating window, and one or two full day water fasts to determine if there is an effect on self-reported symptoms of Long Covid (PASC).
- Trial name
- NCT06214455
- Testing
- Low sugar diet and 10-12 hour eating window, Low sugar diet, 8 hour eating window and fasting
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Pacific Northwest University of Health Sciences
Post COVID-19 Condition, Long COVID
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
- Trial name
- NCT05592418
- Testing
- Rintatolimod
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- AIM ImmunoTech Inc.